Chinese Academy of Medical Sciences COVID-19 vaccine, or IMBCAMS COVID-19 vaccine, traded as Covidful (Chinese: 科维福; pinyin: Kēwéifú), is a COVID-19 vaccine developed by Institute of Medical Biology, Chinese Academy of Medical Sciences [zh].
Clinical trials
In May 2020, Covidful started phase I/II clinical trial with 942 participants in China.[2]
In January 2021, Covidful started phase III clinical trials with 34,020 from Brazil and Malaysia.[3]
Authorizations
Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org.
^Clinical trial number NCT04412538 for "Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19" at ClinicalTrials.gov
^Clinical trial number NCT04659239 for "The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19" at ClinicalTrials.gov